Heart drug sotagliflozin switched mitochondrial energy genes back on — in mice with a thickened heart

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Hypertrophic cardiomyopathy is the most common inherited heart condition, and its energy-starved heart muscle is, at its core, a mitochondrial story: thickened walls that cannot relax, scarring, and oxidative stress. Lexicon's newly published investigator-initiated studies asked whether sotagliflozin's dual blockade does more in that setting than its better-known single-target cousins.

What happened in the thickened-heart mice?

In the Journal of Molecular and Cellular Cardiology Plus study, sotagliflozin treatment in the HCM mouse model normalised diastolic function (how well the heart relaxes and fills), reversed the progression of hypertrophy, and reduced both fibrosis and oxidative stress. In heart tissue, gene sets for mitochondrial energy production were upregulated — the drug appeared to switch the heart's energy machinery back on, not just ease its workload.

What did the second study add?

In the Journal of Clinical Investigation study, sotagliflozin — unlike the SGLT2-only inhibitor empagliflozin — reduced platelet activation and thrombus formation in ex vivo human blood and in animal models, without impairing normal hemostasis. Lexicon attributes the difference to the added SGLT1 blockade. Both studies were investigator-initiated and company-announced; sotagliflozin's established human evidence comes from its earlier programme of roughly 20,000 patients in other indications.

When will human HCM data arrive?

Not yet. The mitochondrial and HCM findings are preclinical; the test that matters is Lexicon's Phase 3 SONATA-HCM trial, with topline results expected in the first quarter of 2027. Until then, the honest summary is: an approved heart drug with a plausible, newly documented mitochondrial mechanism in mice — and a human trial already running to check whether the mechanism matters in patients.

Where the evidence stands

• Established: Sotagliflozin is an approved dual SGLT1/SGLT2 inhibitor with human outcome data in heart failure and diabetes; hypertrophic cardiomyopathy involves impaired cardiac energy production and oxidative stress.
• Preliminary: In a mouse HCM model (Journal of Molecular and Cellular Cardiology Plus, announced Oct 21, 2026), sotagliflozin normalised diastolic function, reversed hypertrophy progression, reduced fibrosis and oxidative stress, and upregulated mitochondrial energy-production gene sets; a second study (Journal of Clinical Investigation) found reduced platelet activation in ex vivo human blood and animal models.
• Absent: Human efficacy data in hypertrophic cardiomyopathy — the Phase 3 SONATA-HCM trial is expected to report topline results in Q1 2027.